Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
<Bundle xmlns="http://hl7.org/fhir">
<id value="bundlepackageleaflet-en-049b5b7dcb707b91228a592e54e9e9d9"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Bundle-uv-epi"/>
</meta>
<language value="en"/>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="None"/>
</identifier>
<type value="document"/>
<timestamp value="2023-06-27T10:09:22Z"/>
<entry>
<fullUrl
value="Composition/composition-en-049b5b7dcb707b91228a592e54e9e9d9"/>
<resource>
<Composition>
<id value="composition-en-049b5b7dcb707b91228a592e54e9e9d9"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Composition-uv-epi"/>
</meta>
<language value="en"/>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en"><a name="Composition_composition-en-049b5b7dcb707b91228a592e54e9e9d9"> </a><p class="res-header-id"><b>Generated Narrative: Composition composition-en-049b5b7dcb707b91228a592e54e9e9d9</b></p><a name="composition-en-049b5b7dcb707b91228a592e54e9e9d9"> </a><a name="hccomposition-en-049b5b7dcb707b91228a592e54e9e9d9"> </a><a name="composition-en-049b5b7dcb707b91228a592e54e9e9d9-en-US"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">Language: en</p><p style="margin-bottom: 0px">Profile: <a href="https://build.fhir.org/ig/HL7/emedicinal-product-info/StructureDefinition-Composition-uv-epi.html">Composition (ePI)</a></p></div><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/08/446/001</p><p><b>status</b>: Final</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/rmswi/ 100000155538}">Package Leaflet</span></p><p><b>category</b>: <span title="Codes:{http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs R}">Raw</span></p><p><b>date</b>: 2022-02-16 13:28:17+0000</p><p><b>author</b>: <a href="Organization-mah-ema.html">Organization ACME industry</a></p><p><b>title</b>: TEST PURPOSES ONLY - privigen</p><h3>Attesters</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Mode</b></td><td><b>Time</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://hl7.org/fhir/composition-attestation-mode official}">Official</span></td><td>2022-02-16 13:28:17+0000</td></tr></table></div>
</text>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="EU/1/08/446/001"/>
</identifier>
<status value="final"/>
<type>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="Package Leaflet"/>
</type>
<category>
<coding>
<system
value="http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs"/>
<code value="R"/>
<display value="Raw"/>
</coding>
</category>
<subject>
<reference
value="MedicinalProductDefinition/mp049b5b7dcb707b91228a592e54e9e9d9"/>
</subject>
<date value="2022-02-16T13:28:17Z"/>
<author>🔗
<reference value="Organization/mah-ema"/>
</author>
<title value="TEST PURPOSES ONLY - privigen"/>
<attester>
<mode>
<coding>
<system
value="http://hl7.org/fhir/composition-attestation-mode"/>
<code value="official"/>
</coding>
</mode>
<time value="2022-02-16T13:28:17Z"/>
</attester>
<section>
<title value="B. Package Leaflet"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="B. Package Leaflet"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
</text>
<emptyReason>
<coding>
<system
value="http://terminology.hl7.org/CodeSystem/list-empty-reason"/>
<code value="unavailable"/>
</coding>
</emptyReason>
<section>
<title value="Package leaflet: Information for the user"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="Package leaflet: Information for the user"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"></div>
</text>
</section>
<section>
<title value="What is in this leaflet"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="What is in this leaflet"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>What is in this leaflet:</p><ol type="1"><li>What Privigen is and what it is used for</li><li>What you need to know before you are given Privigen</li><li>How to use Privigen</li><li>Possible side effects</li><li>How to store Privigen</li><li>Contents of the pack and other information</li></ol></div>
</text>
</section>
<section>
<title value="1. What privigen is and what it is used for"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="1. What privigen is and what it is used for"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>What Privigen is Privigen belongs to the class of medicines called human normal immunoglobulins. Immunoglobulins are also known as antibodies and are blood proteins that help your body to fight infections. How Privigen works Privigen contains immunoglobulins that have been prepared from the blood of healthy people. The medicine works in exactly the same way as the immunoglobulins naturally present in human blood of healthy people. What Privigen is used for Privigen is used for the treatment of adults and children (0-18 years) in the following situations: A) To increase abnormally low immunoglobulin levels in your blood to normal levels (replacement therapy):</p><ol type="1"><li>Patients who are born with a reduced ability or inability to produce immunoglobulins (primary immunodeficiencies (PID)).</li><li>Patients with an acquired immunodeficiency (SID) who suffer from severe or recurrent infections, ineffective antimicrobial treatment and either proven specific antibody failure or serum IgG level of <4 g/l. B) To treat certain inflammatory disorders (immunomodulation). There are 5 groups:</li><li>Patients who do not have enough blood platelets (primary immune thrombocytopenia (ITP) and who are at high risk of bleeding or will have surgery in the near future.</li><li>Patients with Guillain-Barr syndrome. This is an acute disease that is characterised by inflammation of the peripheral nerves that causes severe muscle weakness mainly in the legs and upper limbs.</li><li>Patients with Kawasaki disease. This is an acute disease that primarily affects young children. It is characterised by inflammation of blood vessels throughout the body.</li><li>Patients with chronic inflammatory demyelinating polyneuropathy (CIDP). This is a chronic disease that is characterised by inflammation of the peripheral nerves that causes muscle weakness and/or numbness mainly in the legs and upper limbs.</li><li>Patients with multifocal motor neuropathy (MMN). This is a slowly progressive disease of the motor nerves with weakness of arms and legs.</li></ol></div>
</text>
</section>
<section>
<title value="2. What you need to know before you take privigen"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text
value="2. What you need to know before you take privigen"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Read this section carefully. The information given should be taken into consideration by you and your doctor before you are given Privigen. Do NOT take Privigen</p><p>if you are allergic to human immunoglobulins or to proline.</p><p>if you have developed antibodies against immunoglobulins of the type IgA in your blood.</p><p>if you suffer from hyperprolinaemia type I or II (a genetic disorder causing high levels of the amino acid proline in the blood). This is an extremely rare disorder. Only a few families with this disease are known worldwide. Warnings and precautions Which circumstances increase the risk of having side effects?</p><p>Tell your doctor or healthcare professional prior to treatment if any of the circumstances listed below applies to you:</p><p>You receive this medicine in high doses either on 1 day or over several days and you have a blood group A, B or AB and/or you have an underlying inflammatory condition. In these circumstances, it has been commonly reported that immunoglobulins increase the risk of breakdown of red blood cells (haemolysis).</p><p>You are overweight, are elderly, have diabetes, have been bedridden for a long time, have high blood pressure, have low blood volume (hypovolaemia), have problems with your blood vessels (vascular diseases), have an increased tendency for blood clotting (thrombophilia or thrombotic episodes) or have a disease or a condition which causes your blood to thicken (hyperviscous blood). In these circumstances, immunoglobulins may increase the risk of heart attack (cardiac infarction), stroke, blood clots in the lung (lung embolism), or blockage of a blood vessel in the leg, although only very rarely.</p><p>You are diabetic. Although Privigen does not contain sugar, it may be diluted with a special sugar solution (5% glucose), which could affect your blood sugar level.</p><p>You have or had previously problems with your kidneys or take medicinal products that may harm your kidneys (nephrotoxic medicinal products). In these circumstances, immunoglobulins may increase the risk of serious rapid loss of kidney function (acute renal failure) although only very rarely. Loss of kidney function with fatal outcome has occurred in isolated haemolysis- related cases. What kind of monitoring is required during the infusion? For your personal safety, treatment with Privigen will take place under the supervision of your doctor or healthcare professional. You will usually be observed during the whole infusion and for at least 20 minutes thereafter. In certain circumstances, special precautions may be necessary. Examples of such circumstances are:</p><p>you are receiving Privigen at a high infusion rate or</p><p>you are receiving Privigen for the first time or after a long break in treatment (e.g. several months). In these cases you will be closely observed during the whole infusion and for at least 1 hour afterwards. When may slowing or stopping the infusion be required?</p><p>You may be allergic (hypersensitive) to immunoglobulins without knowing it. However, true allergic reactions are rare. They may occur even if you have previously received human immunoglobulins and had tolerated them well. It may happen particularly if you have developed antibodies against immunoglobulins of the type IgA. In these rare cases allergic reactions such as a sudden fall in blood pressure or shock may occur (see also section 4. Possible side effects ).</p><p>In very rare cases transfusion-related acute lung injury (TRALI) can occur after receiving immunoglobulins. This will lead to non-heart related accumulation of fluid in the air spaces of the lungs (non-cardiogenic pulmonary oedema). You will recognize TRALI by severe difficulty in breathing (respiratory distress), bluish skin (cyanosis), abnormally low level of oxygen in the blood (hypoxia), decrease in blood pressure (hypotension) and increased body temperature (fever). Symptoms typically appear during or within 6 hours after receiving treatment.</p><p>Tell your doctor or healthcare professional immediately if you notice such reactions during the infusion of Privigen. He or she will decide whether to decrease the infusion rate or to stop the infusion completely. Blood tests</p><p>Tell your doctor about your treatment with Privigen prior to having any blood tests. After receiving Privigen, the results of certain blood tests (serological tests) may be impaired for a certain time. Information on safety with respect to infections Privigen is made from human blood plasma (this is the liquid part of the blood). When medicines are made from human blood or plasma, certain measures are put in place to prevent infections being passed on to patients. These include:</p><p>careful selection of blood and plasma donors to make sure those at risk of carrying infections are excluded,</p><p>the testing of each donation and pools of plasma for signs of virus/infections,</p><p>the inclusion of steps in the processing of the blood or plasma that can inactivate or remove viruses. Despite these measures, when medicines prepared from human blood or plasma are administered, the possibility of passing on infection cannot be totally excluded. This also applies to any unknown or emerging viruses and other types of infections. The measures taken are considered effective for enveloped viruses such as human immunodeficiency virus (HIV), hepatitis B virus and hepatitis C virus, and for the non-enveloped hepatitis A virus and parvovirus B19. Immunoglobulins have not been associated with hepatitis A or parvovirus B19 infections, possibly because antibodies against these infections, which are contained in the product, are protective.</p><p>It is strongly recommended that every time you are given a dose of Privigen the name and batch number of the product are recorded in order to maintain a record of the batches used. Other medicines and Privigen</p><p>Tell your doctor or healthcare professional if you are using, have recently used or might use any other medicines. The concomitant use of medicines that increase the excretion of water from your body (loop diuretics) should be avoided during treatment with Privigen. Your doctor will decide whether you should use or continue treatment with loop diuretics. Vaccinations</p><p>Tell your vaccinating doctor prior to a vaccination about your treatment with Privigen. After receiving Privigen, the efficacy of certain vaccinations may be impaired. Affected are vaccinations with live attenuated virus vaccines such as vaccinations against measles, mumps, rubella and varicella. Such vaccinations should be postponed for at least 3 months after the last infusion of Privigen. In the case of measles vaccinations the impairment may persist for up to 1 year. Therefore, your vaccinating doctor should check the effectiveness of the measles vaccination. Pregnancy and breast-feeding</p><p>Tell your doctor or healthcare professional if you are pregnant, plan to become pregnant or are breast-feeding. Your doctor will decide whether you can receive Privigen during your pregnancy or while you are breast-feeding. Medicines containing antibodies have been used in pregnant and breast-feeding women. Long-term experience has shown that no harmful effects during the course of the pregnancy or to the newborn are to be expected. If you receive Privigen while you are breast-feeding the antibodies in this medicine will also be found in the breast milk. Thus, also your baby can receive the protective antibodies. Driving and using machines Patients may experience effects, such as dizziness or nausea, during treatment with Privigen that might affect the ability to drive and use machines. If this happens, you should not drive or use machines until these effects have disappeared. Privigen contains proline You must not take it if you suffer from hyperprolinaemia (see also section 2 What you need to know before you are given Privigen ).</p><p>Tell your doctor prior to treatment. Sodium content This medicine contains less than 2.3 mg sodium (main component of cooking/table salt) in 100 ml. This is equivalent to 0.12% of the recommended maximum daily dietary intake of sodium for an adult.</p></div>
</text>
</section>
<section>
<title value="3. How to take privigen"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="3. How to take privigen"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Privigen is intended solely for the infusion into a vein (intravenous infusion). It is usually administered by your doctor or healthcare professional. Your doctor will calculate the correct dose for you taking into account your weight, the specific circumstances listed under section 2 Warnings and precautions and response to treatment. The dose calculation for children and young patients is not different from that for adults. At the beginning of the infusion you will receive Privigen at a slow infusion rate. If you tolerate this well, your doctor can gradually increase the infusion rate. If you receive more Privigen than you should Overdose is very unlikely to occur because Privigen is usually administered under medical supervision. If, in spite of this, you receive more Privigen than you should, your blood may become too thick (hyperviscous) which might increase the risk of developing blood clots. This may happen particularly if you are a patient at risk, for example if you are elderly or if you suffer from a heart or kidney disease. Tell your doctor if you are known to have medical problems.</p></div>
</text>
</section>
<section>
<title value="4. Possible side effects"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="4. Possible side effects"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Like all medicines, this medicine can cause side effects, although not everybody gets them. Possible side effects may be reduced or even avoided by infusing Privigen at a slow infusion rate. Such side effects may occur even if you have previously received human immunoglobulins and tolerated them well. In rare and isolated cases, the following side effects have been reported with immunoglobulin preparations:</p><p>severe hypersensitivity reactions such as a sudden fall in blood pressure or anaphylactic shock (e.g. you may feel light-headed, dizzy, faint on standing, cold in the hands and feet, sense an abnormal heart beat or chest pain, or have blurred vision) even when you have shown no hypersensitivity on previous infusions,</p><p>Tell your doctor or healthcare professional immediately if you notice such signs during the infusion of Privigen. He or she will decide whether to decrease the infusion rate or to stop the infusion completely.</p><p>formation of blood clots which may be carried off in the blood circulation (thromboembolic reactions) and which may result e.g. in myocardial infarction (e.g. when you have sudden chest pain or shortness of breath), stroke (e.g. when you have a sudden onset of muscle weakness, have loss of sensation and/or balance, decreased alertness or difficulty in speaking), blood clots in the arteries of the lungs (e.g. when you have chest pain, difficulty in breathing or are coughing up blood), deep vein thrombosis (e.g. when you have redness, feel warmth, pain, tenderness, or have a swelling of one or both legs),</p><p>chest pain, chest discomfort, painful respiration due to transfusion related lung injury (TRALI)</p><p>Tell your doctor or healthcare professional immediately if you have any of the above symptoms. Anyone experiencing such symptoms should immediately be transported to a hospital emergency room for evaluation and treatment.</p><p>temporary non-infectious meningitis (reversible aseptic meningitis),</p><p>Tell your doctor or healthcare professional immediately if you have a stiff neck together with one or more of the following symptoms: fever, nausea, vomiting, headache, abnormal sensitivity to light, mental disturbances.</p><p>increase in blood creatinine level,</p><p>proteinuria,</p><p>acute renal failure,</p><p>transient decrease in red blood cells (reversible haemolytic anaemia/haemolysis), anaemia, leukopenia, anisocytosis (including microcytosis). Side effects observed in controlled clinical studies and in post-marketing experience are presented in* rder of decreasing frequency: Very Common (may occur with more than 1 in 10 patients): Headache (including sinus headache, migraine, head discomfort, tension headache), pain (including ba ck pain, pain in extremity, pain in joints and bones (arthralgia), neck pain, facial pain), fever (includin g chills), flu-like illness (including runny nose (nasopharyngitis), sore throat (pharyngolaryngeal pain), blisters in mouth and throat (oropharyngeal blistering), throat tightness. Common (may occur with up to 1 in 10 patients): Temporary lowering of red blood cell count (anaemia), breakdown of red blood cells (haemolysis including haemolytic anaemia) , decreased number of white blood cells (leukopenia), hypersensitivity, dizziness (including vertigo), high blood pressure (hypertension), flushing (including hot flush, hyperaemia), hypotension (including decreased blood pressure), breathlessness (dyspnoea including chest pain, chest discomfort, painful breathing), upset stomach (nausea), vomiting, loose stools (diarrhea), stomach pain, skin disorder (including rash, itching (pruritus), hives (urticaria), maculopapular rash, redness of the skin (erythema), peeling of the skin (skin exfoliation)), pain in the muscles (including muscle cramps and rigidity), tiredness (fatigue), physical weakness (asthenia), weakness in the muscles. Routine laboratory tests may commonly reveal changes to liver functions (hyperbilirubinaemia) as well as changes in blood count (e.g. Coombs (direct) test positive), increased alanine aminotransferase, increased aspartate aminotransferase, increased blood lactate dehydrogenase). Uncommon (may occur with up to 1 in 100 patients): Temporary non-infectious meningitis (reversible aseptic meningitis), irregularity of red blood cell shape (microscopic finding), presence of high platelet counts in the blood (thrombocytosis), sleepiness, shiver (tremor), palpitations, tachycardia, thromboembolic events, lack of blood supply to the lower extremities causing e.g. pain when walking (peripheral vascular disorder), presence of an excess of serum proteins in the urine (proteinuria including increased blood creatinine), injection site pain (including infusion site discomfort). In isolated cases (post-marketing experience), the following have been observed in patients treated with Privigen: abnormally low level of specific white blood cells called neutrophils (decreased neutrophils counts), anaphylactic shock, painful respiration due to transfusion related lung injury (TRALI) and acute renal failure. The haemolytic anaemia cases after controlled clinical study completion were observed at significantly reduced frequency due to enhancements in the Privigen manufacturing process.</p><p>If you get any side effects, talk to your doctor or healthcare professional. This includes any possible side effects not listed in this leaflet. Please also refer to section 2 What you need to know before you are given Privigen for additional details on circumstances which increase the risk of side effects. Reporting of side effects If you get any side effects, talk to your doctor or healthcare professional. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.</p></div>
</text>
</section>
<section>
<title value="5. How to store privigen"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="5. How to store privigen"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Keep this medicine out of the sight and reach of children.</p><p>Do not use this medicine after the expiry date which is stated on the outer carton and the vial label after EXP. The expiry date refers to the last day of that month.</p><p>Because the solution contains no preservative, your healthcare professional must infuse it immediately after opening the vial.</p><p>Do not store above 25 C.</p><p>Do not freeze.</p><p>Keep the vial in the outer carton in order to protect from light.</p><p>Do not use this medicine if you notice that the solution is cloudy or contains particles floating within the solution.</p></div>
</text>
</section>
<section>
<title value="6. Contents of the pack and other information"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="6. Contents of the pack and other information"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>What Privigen contains</p><p>The active substance is human normal immunoglobulin (antibodies of the type IgG). Privigen contains 100 mg/ml (10%) human protein of which at least 98% is IgG. The approximate percentage of IgG subclasses is as follows: IgG1 ...................... 69 % IgG2 ...................... 26 % IgG3 ........................ 3 % IgG4 ........................ 2 % This medicine contains trace amounts of IgA (not more than 25 micrograms/ml).</p><p>The other ingredients (excipients) are the amino acid proline, water for injections, and hydrochloric acid or sodium hydroxide (for pH adjustment). What Privigen looks like and contents of the pack Privigen is presented as a solution for infusion. The solution is clear or slightly opalescent and colourless to pale-yellow. Pack sizes: 1 vial (2.5 g/25 ml, 5 g/50 ml, 10 g/100 ml, 20 g/200 ml or 40 g/400 ml), 3 vials (10 g/100 ml or 20 g/200 ml). Not all pack sizes may be marketed. Marketing Authorisation Holder and Manufacturer CSL Behring GmbH Emil-von-Behring-Strasse D-35041 Marburg Germany For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder: Belgi /Belgique/Belgien CSL Behring NV T l/Tel: +32 15 28 89 Luxembourg/Luxemburg CSL Behring NV T l/Tel: +32 15 28 89</p><h2 id="-359-2-810-3magyarorsz-g-csl-behring-kft-tel-36-1-213-4-esk-republika-csl-behring-sro-tel-420-702-137-malta-am-mangion-ltd-tel-356-2397-6danmark-csl-behring-aps-tlf-45-4520-1nederland-csl-behring-bv-tel-31-85-111-96-deutschland-csl-behring-gmbh-tel-49-69-30584norge-csl-behring-ab-tlf-46-8-544-966-eesti-centralpharma-communications-o-tel-3726015-sterreich-csl-behring-gmbh-tel-43-1-80101-2-csl-behring--30-210-7255-polska-csl-behring-sp-z-oo-tel-48-22-213-22-espa-a-csl-behring-sa-tel-34-933-67-1portugal-csl-behring-lda-tel-351-21-782-62-france-csl-behring-sa-t-l-33-1-53-58-54-hrvatska-marti-farm-doo-tel-385-1-5588rom-nia-prisum-healthcare-srl-tel-40-21-322-01-slovenija-emmes-biopharma-global-sro---podru-nica-v-sloveniji-tel-386-41-42-0ireland-csl-behring-gmbh-tel-49-69-305-17slovensk-republika-csl-behring-sro-tel-421-911-653-sland-csl-behring-ab-s-mi-46-8-544-966-suomifinland-csl-behring-ab-puhtel-46-8-544-966-italia-csl-behring-spa-tel-39-02-34964-sverige-csl-behring-ab-tel-46-8-544-966-csl-behring--30-210-7255-united-kingdom-northern-ireland-csl-behring-gmbh-tel-49-69-305-17latvija-centralpharma-communications-sia-tel-371-6-7450lietuva-centralpharma-communications-uab-tel-370-5-243-0this-leaflet-was-last-revised-in-detailed-information-on-this-medicine-is-available-on-the-european-medicines-agency-website-httpwwwemaeuropaeu">: +359 2 810 3Magyarorsz g CSL Behring Kft. Tel: +36 1 213 4 esk republika CSL Behring s.r.o. Tel: +420 702 137 Malta AM Mangion Ltd. Tel: +356 2397 6Danmark CSL Behring ApS Tlf: +45 4520 1Nederland CSL Behring BV Tel: +31 85 111 96 Deutschland CSL Behring GmbH Tel: +49 69 30584Norge CSL Behring AB Tlf: +46 8 544 966 Eesti CentralPharma Communications O Tel: +3726015 sterreich CSL Behring GmbH Tel: +43 1 80101 2 CSL Behring<br/>: +30 210 7255 Polska CSL Behring Sp. z o.o. Tel.: +48 22 213 22 Espa a CSL Behring S.A. Tel: +34 933 67 1Portugal CSL Behring Lda Tel: +351 21 782 62 France CSL Behring SA T l: +33 1 53 58 54 Hrvatska Marti Farm d.o.o. Tel: +385 1 5588Rom nia Prisum Healthcare S.R.L. Tel: +40 21 322 01 Slovenija EMMES BIOPHARMA GLOBAL s.r.o. - podru nica v Sloveniji Tel: +386 41 42 0Ireland CSL Behring GmbH Tel: +49 69 305 17Slovensk republika CSL Behring s.r.o. Tel: +421 911 653 sland CSL Behring AB S mi: +46 8 544 966 Suomi/Finland CSL Behring AB Puh/Tel: +46 8 544 966 Italia CSL Behring S.p.A. Tel: +39 02 34964 Sverige CSL Behring AB Tel: +46 8 544 966<br/>CSL Behring<br/>: +30 210 7255 United Kingdom (Northern Ireland) CSL Behring GmbH Tel: +49 69 305 17Latvija CentralPharma Communications SIA Tel: +371 6 7450Lietuva CentralPharma Communications UAB Tel: +370 5 243 0This leaflet was last revised in. Detailed information on this medicine is available on the European Medicines Agency website: <a href="http://www.ema.europa.eu">http://www.ema.europa.eu</a>.</h2><p>The following information is intended for healthcare professionals only: Posology and method of administration The dosage recommendations are summarised in the following table: Indication Dose Frequency of injections Replacement therapy Primary immunodeficiency syndromes (PID) starting dose: 0.4 - 0.8 g/kg bw maintenance dose: 0.2 - 0.8 g/kg bw every 3 to 4 weeks to obtain IgG trough levels of at least 6 g/l Secondary immunodeficiencies (as defined in 4.1) 0.2 - 0.4 g/kg bw every 3 to 4 weeks to obtain IgG trough levels of at least 6 g/l Immunomodulation Primary immune thrombocytopenia (ITP) 0.8 - 1 g/kg bw or on day 1, possibly repeated once within 3 days 0.4 g/kg bw/d for 2 to 5 days Guillain-Barr syndrome 0.4 g/kg bw/d for 5 days Kawasaki disease 2 g/kg bw in one dose in association with acetylsalicylic acid Chronic inflammatory demyelinating polyneuropathy (CIDP)* starting dose: 2 g/kg bw in divided doses over 2 to 5 days maintenance dose: 1 g/kg bw every 3 weeks over 1 to 2 days Multifocal Motor Neuropathy (MMN) starting dose : 2 g/kg bw over 2 to 5 consecutive days maintenance dose: 1 g/kg bw or every 2 to 4 weeks or 2 g/kg bw every 4 to 8 weeks over 2 to 5 days Method of administration For intravenous use. Human normal immunoglobulin should be infused intravenously at an initial infusion rate of 0.3 ml/kg bw/hr for approximately 30 min. If well tolerated, the rate of administration may gradually be increased to 4.8 ml/kg bw/hr. In PID patients who have tolerated the infusion rate of 4.8 ml/kg bw/hr well, the rate may be further increased gradually to a maximum of 7.2 ml/kg bw/hr. If dilution prior to infusion is desired, Privigen may be diluted with 5% glucose solution to a final concentration of 50 mg/ml (5%). Special precautions In case of adverse reaction, either the rate of administration must be reduced or the infusion stopped. It is strongly recommended that every time Privigen is administered to a patient, the name and batch number of the product are recorded in order to maintain a link between the patient and the batch of the product. Incompatibilities This medicinal product must not be mixed with other medicinal products except those mentioned in the section below. Special precautions for disposal and other handling The product should be brought to room or body temperature before use. A vented infusion line should be used for the administration of Privigen. Always pierce the stopper at its centre, within the marked area. The solution should be clear or slightly opalescent and colourless or pale yellow. Solutions that are cloudy or have deposits should not be used. If dilution is desired, 5% glucose solution is recommended. For obtaining an immunoglobulin solution of 50 mg/ml (5%), Privigen 100 mg/ml (10%) should be diluted with an equal volume of the glucose solution. Aseptic technique must be strictly observed during the dilution of Privigen. Once the vial has been entered under aseptic conditions, its contents should be used promptly. Because the solution contains no preservative, Privigen should be infused as soon as possible. Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p></div>
</text>
</section>
</section>
</Composition>
</resource>
</entry>
<entry>
<fullUrl
value="MedicinalProductDefinition/mp049b5b7dcb707b91228a592e54e9e9d9"/>
<resource>
<MedicinalProductDefinition>
<id value="mp049b5b7dcb707b91228a592e54e9e9d9"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/MedicinalProductDefinition-uv-epi"/>
</meta>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><a name="MedicinalProductDefinition_mp049b5b7dcb707b91228a592e54e9e9d9"> </a><p class="res-header-id"><b>Generated Narrative: MedicinalProductDefinition mp049b5b7dcb707b91228a592e54e9e9d9</b></p><a name="mp049b5b7dcb707b91228a592e54e9e9d9"> </a><a name="hcmp049b5b7dcb707b91228a592e54e9e9d9"> </a><a name="mp049b5b7dcb707b91228a592e54e9e9d9-en-US"> </a><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/08/446/001</p><p><b>type</b>: <span title="Codes:{http://hl7.org/fhir/medicinal-product-type MedicinalProduct}">Medicinal Product</span></p><p><b>domain</b>: <span title="Codes:{http://hl7.org/fhir/medicinal-product-domain Human}">Human use</span></p><p><b>status</b>: <span title="Codes:{http://hl7.org/fhir/publication-status active}">active</span></p><p><b>legalStatusOfSupply</b>: <span title="Codes:{https://spor.ema.europa.eu/rmswi 100000072084}">Medicinal product subject to medical prescription</span></p><blockquote><p><b>name</b></p><p><b>productName</b>: Privigen 100 mg/ml solution for infusion</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000001}">Full name</span></p><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000002}">Invented name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000003}">Scientific name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000004}">Strength part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000005}">Pharmaceutical dose form part</span></p></blockquote><h3>Usages</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Country</b></td><td><b>Jurisdiction</b></td><td><b>Language</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{urn:iso:std:iso:3166 EU}">EU</span></td><td><span title="Codes:{urn:iso:std:iso:3166 EU}">EU</span></td><td><span title="Codes:{urn:ietf:bcp:47 en}">en</span></td></tr></table></blockquote></div>
</text>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="EU/1/08/446/001"/>
</identifier>
<type>
<coding>
<system value="http://hl7.org/fhir/medicinal-product-type"/>
<code value="MedicinalProduct"/>
<display value="Medicinal Product"/>
</coding>
</type>
<domain>
<coding>
<system value="http://hl7.org/fhir/medicinal-product-domain"/>
<code value="Human"/>
<display value="Human use"/>
</coding>
</domain>
<status>
<coding>
<system value="http://hl7.org/fhir/publication-status"/>
<code value="active"/>
<display value="active"/>
</coding>
</status>
<legalStatusOfSupply>
<coding>
<system value="https://spor.ema.europa.eu/rmswi"/>
<code value="100000072084"/>
<display
value="Medicinal product subject to medical prescription"/>
</coding>
</legalStatusOfSupply>
<name>
<productName value="Privigen 100 mg/ml solution for infusion"/>
<type>
<coding>
<system value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000001"/>
<display value="Full name"/>
</coding>
</type>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000002"/>
<display value="Invented name part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000003"/>
<display value="Scientific name part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000004"/>
<display value="Strength part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000005"/>
<display value="Pharmaceutical dose form part"/>
</coding>
</type>
</part>
<usage>
<country>
<coding>
<system value="urn:iso:std:iso:3166"/>
<code value="EU"/>
<display value="EU"/>
</coding>
</country>
<jurisdiction>
<coding>
<system value="urn:iso:std:iso:3166"/>
<code value="EU"/>
<display value="EU"/>
</coding>
</jurisdiction>
<language>
<coding>
<system value="urn:ietf:bcp:47"/>
<code value="en"/>
<display value="en"/>
</coding>
</language>
</usage>
</name>
</MedicinalProductDefinition>
</resource>
</entry>
</Bundle>
IG © 2021+ Gravitate Health Project. Package hl7.eu.fhir.ghepi#0.1.0 based on FHIR 5.0.0. Generated 2024-10-14
Links: Table of Contents |
QA Report
The Gravitate Health project has received funding from the IMI 2 Joint Undertaking under grant agreement No 945334.
This joint undertaking receives support from the EU H2020 research and innovation programme and EFPIA.
